Zenas BioPharma Secures $250 Million Debt, Prepares Obexelimab FDA Submission
Zenas BioPharma will submit obexelimab BLA for IgG4-RD to the FDA in Q2 2026 and EMA MAA in H2 2026 after its Phase 3 INDIGO trial showed a 56% flare risk reduction. The company secured $250 million in non-dilutive debt to fund development of ZB014, orelabrutinib and ZB021.
1. Obexelimab INDIGO Results and Filings
Positive Phase 3 INDIGO results demonstrated a 56% reduction in IgG4-RD flare risk and significant activity across all four key secondary endpoints. Zenas plans to submit a Biologics License Application to the FDA in Q2 2026 and a Marketing Authorization Application to the EMA in H2 2026.
2. Broad Clinical Pipeline Advancements
Zenas expects topline Phase 2 SunStone trial results for obexelimab in SLE in Q4 2026. The half-life–extended anti-CD-19/FcγRIIb antibody ZB014 is progressing toward clinical development with potential once-monthly dosing. Orelabrutinib’s global Phase 3 PPMS trial is ongoing, a naSPMS study is set to start in Q1 2026, and the oral IL-17AA/AF inhibitor ZB021 is slated for a Phase 1 trial in 2Q 2026 with initial data by year-end.
3. $250 Million Non-Dilutive Financing Secured
Zenas secured up to $250 million in non-dilutive, multi-tranche debt financing from Pharmakon to strengthen its balance sheet. The funding will support potential obexelimab commercialization and ongoing development of ZB014, orelabrutinib and ZB021 programs.